Clinical trial
Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome
NCT00266565 · Children's Hospital Medical Center, Cincinnati, Other · Completed
Key facts
| NCT number | NCT00266565 |
|---|---|
| Title | Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome |
| Official title | A Phase I/II Study of the Effect of Intravenous Anti-IL-5 (Mepolizumab) SB 240563 on the Outcome and Management of Hypereosinophilic Syndromes |
| Lead sponsor | Children's Hospital Medical Center, Cincinnati, Other |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Hypereosinophilic Syndromes, Eosinophilic Gastroenteritis, Churg-Strauss Syndrome, Eosinophilic Esophagitis |
| Intervention type | Drug |
| Interventions | Mepolizumab |
| Enrollment | 24 |
| Start date | Dec 1, 2001 |
| Primary completion | Apr 1, 2005 |
| Completion | Apr 1, 2005 |
| First posted | Dec 19, 2005 |
| Last update posted | Jul 29, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: